Holen Sie sich die Stockscreener-App
192.95
0.83%
1.58
Handel nachbörslich:
193.23
0.28
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Biogen Inc Aktie (BIIB) Neueste Nachrichten
BIIB Advances Alzheimer's Disease Drug Despite Study Missing Main Goal - TradingView
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity (BIIB) - Seeking Alpha
Piper Sandler raises Biogen stock price target on drug development - Investing.com
Biogen stock (US09062X1037): Alzheimer’s data and earnings keep focus on pipeline - AD HOC NEWS
Guggenheim reiterates Biogen stock rating on Alzheimer’s drug data - Investing.com
Guggenheim reiterates Biogen stock rating on Alzheimer’s drug data By Investing.com - Investing.com Canada
Biogen’s Alzheimer’s Research Signals a New Era for Biotech - Kalkine Media
Biogen stock (US09062X1037): $5.3 billion Apellis takeover reshapes growth story - AD HOC NEWS
Biogen to push ahead with experimental Alzheimer’s drug despite mid-stage trial miss - IndiaMedToday
Inside Biotech: Biogen’s Alzheimer’s setback still points to a bigger shift in the field - Proactive financial news
Biogen Slides 3.9% as Investors Digest Mixed Alzheimer's Tau Data Alongside Apellis Deal Close - Moomoo
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push - sharewise.com
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
Apellis Pharmaceuticals (APLS) CFO equity awards converted in Biogen cash-and-CVR merger - Stock Titan
Biogen buys Apellis (APLS) for $41 cash plus CVR per share - Stock Titan
Biogen–Apellis (NASDAQ: APLS) deal closes with $41 cash plus CVR per share - Stock Titan
Biogen to acquire Apellis (NASDAQ: APLS) for $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) CTO reports equity conversion in Biogen cash and CVR buyout - Stock Titan
Biogen deal: Apellis (APLS) director’s shares and options cashed out - Stock Titan
Biogen–Apellis (APLS) deal pays $41 cash plus CVRs as executive equity is restructured - Stock Titan
Biogen buys Apellis (NASDAQ: APLS) at $41 per share plus CVR - Stock Titan
Apellis (NASDAQ: APLS) chief people officer reports cash-out and new stock grants in Biogen merger - Stock Titan
Apellis (NASDAQ: APLS) director fully cashes out in Biogen merger swap - Stock Titan
Biogen–Apellis (NASDAQ: APLS) merger gives $41 cash plus CVRs to shareholders - Stock Titan
Apellis (NASDAQ: APLS) CMO reports stock and option changes in Biogen cash-plus-CVR buyout - Stock Titan
Biogen Justifies Phase III Trial For Anti-Tau Drug Despite Phase II Miss - Citeline News & Insights
Biogen advances Alzheimer’s drug on suggestion of benefit - The Boston Globe
Evercore ISI reinstates Biogen stock with Outperform rating - Investing.com
Biogen (APLS counterparty) closes Apellis tender offer and merger with cash and CVR deal - Stock Titan
Biogen Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Biogen stock (US09062X1037): closes $5.3B Apellis deal - AD HOC NEWS
Best Healthcare Stocks to Buy in 2026 - Yahoo Finance
Biogen Inc. on Pace for Largest Percent Decrease Since April 2025 -- Data Talk - Moomoo
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
Oppenheimer Raises Biogen Price Target to $300 From $275, Maintains Outperform Rating - marketscreener.com
Biogen to advance experimental Alzheimer's drug despite mid-stage trial miss - Reuters
Biogen’s SKYCLARYS Formulation Study: What a New Liquid Tablet Could Mean for BIIB Investors - TipRanks
Biogen Inc. (BIIB) Completes Acquisition of Apellis Pharmaceuticals - GuruFocus
Biogen pushing tau drug forward despite Alzheimer’s study failure - BioPharma Dive
Why Is Biogen Stock Falling Thursday? - Benzinga
Biogen Inc stock (US09062X1037): Recent developments and market position - AD HOC NEWS
Biogen Completes Acquisition of Apellis Pharmaceuticals, Expanding Portfolio with EMPAVELI and SYFOVRE for Growth in Nephrology and Ophthalmology 1 - Minichart
Biogen slides 3.9% as investors digest mixed Alzheimer’s tau data alongside Apellis deal close - Quiver Quantitative
Apellis Pharmaceuticals Announces Merger With Biogen, Delisting from Nasdaq, and Convertible Notes Repurchase/Conversion Options - Minichart
Jefferies reiterates Biogen stock rating on Alzheimer’s drug data By Investing.com - Investing.com Canada
Jefferies reiterates Biogen stock rating on Alzheimer’s drug data - Investing.com
Biogen Completes Apellis Acquisition to Strengthen Growth - TipRanks
Apellis Completes Biogen Merger and Goes Private - TipRanks
Biogen stock maintains Outperform at Mizuho after trial results By Investing.com - Investing.com Canada
Biogen stock maintains Outperform at Mizuho after trial results - Investing.com
Biogen Completes Acquisition of Apellis Pharmaceuticals - Intellectia AI
Wolfe Research reiterates Peerperform on Biogen stock after trial miss By Investing.com - Investing.com Canada
Biogen (APLS) closes Apellis buyout at $41 per share plus CVRs and delists stock - Stock Titan
Biogen Finalizes Apellis CVR Terms (Up To $4) And Secures $2 Billion Term Loan Facilities - TradingView
Biogen (BIIB) closes $5.3B Apellis deal, adds EMPAVELI and SYFOVRE growth - Stock Titan
Biogen stock gains as Stifel maintains Buy on tau drug progress - Investing.com
Biogen to merge Apellis (NASDAQ: APLS) after tender offer closes - Stock Titan
Biogen reports phase 2 Alzheimer’s drug trial results - Investing.com
Apellis (APLS) tendered 82.4% of shares; Biogen to close merger May 14, 2026 - Stock Titan
Biogen posts trial data for Alzheimer’s drug (BIIB:NASDAQ) - Seeking Alpha
Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study - statnews.com
Biogen reports phase 2 Alzheimer’s drug trial results By Investing.com - Investing.com Canada
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease - Business Wire
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease - Biogen
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):